Effect of a zinc phosphate suspension of a long-acting somatostatin analog on postprandial plasma glucose, triglyceride and glucagon concentrations in alloxan diabetic dogs.
The effects of a zinc phosphate suspension of a long-acting, reportedly selective somatostatin analog, Des-Ala1,Gly2 [His4,5,D-Try]-somatostatin (100 micrograms/kg) on postprandial plasma glucose, glucagon, xylose and triglyceride levels were evaluated in alloxan diabetic dogs. Compared to the analog in aqueous solution, the zinc phosphate suspension had a more gradual onset of action in suppressing plasma glucose and xylose levels but a similar onset of action on suppression of plasma triglyceride and glucagon responses. On all these responses, the zinc suspension had a duration of action (greater than 6 hrs) at least three times as long as the aqueous solution. We conclude that such a somatostatin analog in zinc phosphate suspension may have a sufficient duration of action to be useful as an adjunct to insulin in the treatment of diabetes mellitus.
D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D004285:Dogs; D005223:Fats / Q000032:analysis; D005243:Feces / Q000032:analysis; D005934:Glucagon / Q000097:blood*; D010710:Phosphates / Q000494:pharmacology*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology; D013535:Suspensions; D014280:Triglycerides / Q000097:blood*; D014994:Xylose / Q000378:metabolism; D015032:Zinc / Q000494:pharmacology*; D017967:Zinc Compounds
D001786:Blood Glucose; D005223:Fats; D010710:Phosphates; D013535:Suspensions; D014280:Triglycerides; D017967:Zinc Compounds; C043952:zinc phosphate; D013004:Somatostatin; C030740:Wy 41747; D005934:Glucagon; D014994:Xylose; D015032:Zinc